October 2022

First patient dosed in multicentre Phase II study of LEVI-04 in osteoarthritis patients. Multiple arm, multi-centre, placebo-controlled study to evaluate five monthly infusions of LEVI-04 for the treatment of pain due to osteoarthritis of the knee. ID: NCT05618782

April 2022

Case Study interview with Simon Westbrook, CEO of Levicept in Bioprocess Online discussing his experience in selecting and working with a global CDMO partner, and the value Lonza brought to his virtual company.

September 2021

Closing of £35m Series B financing. All existing investors – Medicxi, Advent Life Sciences and Gilde Healthcare – participate, joined by Pfizer Ventures. Funds to support further development of LEVI-04 including Phase II study.

March 2021

Phase I clinical trial of LEVI-04 successfully completed. Study in osteoarthritis patients confirmed favourable safety, tolerability and pharmacokinetic profile. Analysis of biomarkers indicated target engagement and provided early supporting evidence of efficacy / proof-of-concept. IDNCT03227796

February 2018

Interview with Simon Westbrook, CEO of Levicept in Labiotech by Alex Dale – This Biotech Could Replace Opioids with Safe and Effective Pain Relief for Osteoarthritis.

September 2014

Index Ventures, Advent Life Sciences and Gilde Healthcare invest £10 million Series A financing to develop LEVI-04 to proof-of-concept first-in-human clinical trials

April 2014

Innovate UK awards £2.4 million grant

February 2014

February 2014

Levicept is industrial SME in €5.9M PAINCAGE Consortium.

September 2013

Simon Westbrook acquires asset from Pfizer Ltd

March 2012

Index Ventures awards seed funding